BriaCell Therapeutics Corp. (NASDAQ:BCTXW) Short Interest Update

BriaCell Therapeutics Corp. (NASDAQ:BCTXW) was the recipient of a large decrease in short interest in January. As of January 15th, there was short interest totaling 4,166 shares, a decrease of 21.8% from the December 31st total of 5,328 shares. Based on an average daily trading volume, of 173,275 shares, the short-interest ratio is presently 0.0 days. Based on an average daily trading volume, of 173,275 shares, the short-interest ratio is presently 0.0 days.

BriaCell Therapeutics Stock Down 25.2%

Shares of BCTXW stock traded down $0.00 during midday trading on Friday, reaching $0.01. 66,043 shares of the company were exchanged, compared to its average volume of 116,967. The company’s 50 day moving average price is $0.04 and its two-hundred day moving average price is $0.04. BriaCell Therapeutics has a 12 month low of $0.00 and a 12 month high of $0.25.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on the development of novel immunotherapeutic treatments for breast cancer and other solid tumors. The company’s research strategy centers on harnessing the body’s immune system to recognize and attack cancer cells, with an emphasis on off-the-shelf allogeneic platforms that can be readily administered without the need for patient-specific manufacturing.

The company’s lead candidate, Bria-IMT, is derived from a human breast tumor cell line engineered to express immune-stimulatory molecules designed to trigger both innate and adaptive anti-tumor responses.